Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypyrovalerone (MDPV) induce differential cytotoxic effects in bovine brain microvessel endothelial cells

Neuroscience Letters

Volumn 629, Issue , 2016, Pages 125-130

  Rosas Hernandez, Hector ^a   Cuevas, Elvis ^a   Lantz, Susan M ^a   Rice, Kenner C ^b   Gannon, Brenda M ^c   Fantegrossi, William E ^c   Gonzalez, Carmen ^d   Paule, Merle G ^a   Ali, Syed F ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

Author keywords

Blood brain barrier; Cytotoxicity; MDMA; MDPV; Methamphetamine

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYPYROVALERONE; CENTRAL STIMULANT AGENT; LACTATE DEHYDROGENASE; METHAMPHETAMINE; NITRIC OXIDE; PSYCHOSTIMULANT AGENT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; 3,4-METHYLENEDIOXYPYROVALERONE; DESIGNER DRUG; DOPAMINE RECEPTOR STIMULATING AGENT; MIDOMAFETAMINE; PYRROLIDINE DERIVATIVE; SEROTONIN RECEPTOR AFFECTING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BOVINE; BRAIN CAPILLARY ENDOTHELIAL CELL; CELL DISRUPTION; CELL PROLIFERATION; CELL VACUOLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; ENZYME RELEASE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; MICROVASCULATURE; NECROSIS; PATHOLOGY;

ANIMALS; BENZODIOXOLES; BLOOD-BRAIN BARRIER; CATTLE; CELL PROLIFERATION; DESIGNER DRUGS; DOPAMINE AGENTS; ENDOTHELIAL CELLS; METHAMPHETAMINE; MICROVESSELS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NECROSIS; NITRIC OXIDE; PYRROLIDINES; REACTIVE OXYGEN SPECIES; SEROTONIN AGENTS;

EID: 84978924769     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2016.06.029     Document Type: Article

References (46)

1. [1] Burns, L., World drug report 2013 united nations office on drugs and crime. Drug Alcohol Rev., 33, 2014 216–216.
2. [2] Halpin, L.E., Collins, S.A., Yamamoto, B.K., Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci. 97 (2014), 37–44.
3. [3] Cadet, J.L., Bisagno, V., Milroy, C.M., Neuropathology of substance use disorders. Acta Neuropathol. 127 (2014), 91–107.
4. [4] Karila, L., Megarbane, B., Cottencin, O., Lejoyeux, M., Synthetic cathinones: a new public health problem. Curr. Neuropharmacol. 13 (2015), 12–20.
5. [5] Schneir, A., Ly, B.T., Casagrande, K., Darracq, M., Offerman, S.R., Thornton, S., Smollin, C., Vohra, R., Rangun, C., Tomaszewski, C., Gerona, R.R., Comprehensive analysis of bath salts purchased from California stores and the internet. Clin. Toxicol. (Phila.) 52 (2014), 651–658.
6. [6] C.I.S. 3190, Synthetic Drug Abuse Prevention Act of 2012, 2016.
7. [7] Baumann, M.H., Partilla, J.S., Lehner, K.R., Thorndike, E.B., Hoffman, A.F., Holy, M., Rothman, R.B., Goldberg, S.R., Lupica, C.R., Sitte, H.H., Brandt, S.D., Tella, S.R., Cozzi, N.V., Schindler, C.W., Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘Bath salts’ products. Neuropsychopharmacology 38 (2013), 552–562.
8. [8] Verma, V., Classic studies on the interaction of cocaine and the dopamine transporter. Clin. Psychopharmacol. Neurosci. 13 (2015), 227–238.
9. [9] Fleckenstein, A.E., Metzger, R.R., Gibb, J.W., Hanson, G.R., A rapid and reversible change in dopamine transporters induced by methamphetamine. Eur. J. Pharmacol. 323 (1997), R9–10.
10. [10] Sandoval, V., Riddle, E.L., Ugarte, Y.V., Hanson, G.R., Fleckenstein, A.E., Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J. Neurosci. 21 (2001), 1413–1419.
11. [11] Beck, O., Franzen, L., Backberg, M., Signell, P., Helander, A., Intoxications involving MDPV in Sweden during 2010–2014: results from the STRIDA project. Clin. Toxicol. (Phila.) 53 (2015), 865–873.
12. [12] O'Shea, E., Urrutia, A., Green, A.R., Colado, M.I., Current preclinical studies on neuroinflammation and changes in blood-brain barrier integrity by MDMA and methamphetamine. Neuropharmacology 87 (2014), 125–134.
13. [13] Chow, B.W., Gu, C., The molecular constituents of the blood-brain barrier. Trends Neurosci. 38 (2015), 598–608.
14. [14] Moretti, R., Pansiot, J., Bettati, D., Strazielle, N., Ghersi-Egea, J.F., Damante, G., Fleiss, B., Titomanlio, L., Gressens, P., Blood-brain barrier dysfunction in disorders of the developing brain. Front. Neurosci., 9, 2015, 40.
15. [15] Parikh, N.U., Aalinkeel, R., Reynolds, J.L., Nair, B.B., Sykes, D.E., Mammen, M.J., Schwartz, S.A., Mahajan, S.D., Galectin-1 suppresses methamphetamine induced neuroinflammation in human brain microvascular endothelial cells: neuroprotective role in maintaining blood brain barrier integrity. Brain Res. 1624 (2015), 175–187.
16. [16] Rosas-Hernandez, H., Cuevas, E., Lantz-McPeak, S.M., Ali, S.F., Gonzalez, C., Prolactin protects against the methamphetamine-induced cerebral vascular toxicity. Curr. Neurovasc. Res. 10 (2013), 346–355.
17. [17] Bowyer, J.F., Ali, S., High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 60 (2006), 521–532.
18. [18] Sharma, H.S., Ali, S.F., Alterations in blood-brain barrier function by morphine and methamphetamine. Ann. N. Y. Acad. Sci. 1074 (2006), 198–224.
19. [19] Bowyer, J.F., Robinson, B., Ali, S., Schmued, L.C., Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure. Synapse 62 (2008), 193–204.
20. [20] Martins, T., Baptista, S., Goncalves, J., Leal, E., Milhazes, N., Borges, F., Ribeiro, C.F., Quintela, O., Lendoiro, E., Lopez-Rivadulla, M., Ambrosio, A.F., Silva, A.P., Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9. Brain Res. 1411 (2011), 28–40.
21. [21] Rubio-Araiz, A., Perez-Hernandez, M., Urrutia, A., Porcu, F., Borcel, E., Gutierrez-Lopez, M.D., O'Shea, E., Colado, M., 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) disrupts blood-brain barrier integrity through a mechanism involving P2X(7) receptors I. Int. J. Neuropsychopharmcol., 17 2014, 1243–1255.
22. [22] Sharma, H.S., Ali, S.E., Acute administration of 3,4-methylenedioxymethamphetamine induces profound hyperthermia, blood-brain barrier disruption, brain edema formation, and cell injury an experimental study in rats and mice using biochemical and morphologic approaches. Ann. N. Y. Acad. Sci. 1139 (2008), 242–258.
23. [23] Audus, K.L., Borchardt, R.T., Bovine brain microvessel endothelial cell monolayers as a model system for the blood-brain barrier. Ann. N. Y. Acad. Sci. 507 (1987), 9–18.
24. [24] Decker, T., Lohmann-Matthes, M.L., A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 115 (1988), 61–69.
25. [25] Rayamajhi, M., Zhang, Y., Miao, E.A., Detection of pyroptosis by measuring released lactate dehydrogenase activity. Methods Mol. Biol. 1040 (2013), 85–90.
26. [26] Miranda, K.M., Espey, M.G., Wink, D.A., A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5 (2001), 62–71.
27. [27] Wang, H., Joseph, J.A., Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic. Biol. Med. 27 (1999), 612–616.
28. [28] Mueller, M., Goodwin, A.K., Ator, N.A., McCann, U.D., Ricaurte, G.A., Metabolism and disposition of 3,4-methylenedioxymethamphetamine (ecstasy) in baboons after oral administration: comparison with humans reveals marked differences. J. Pharmacol. Exp. Ther. 338 (2011), 310–317.
29. [29] Cruickshank, C.C., Dyer, K.R., A review of the clinical pharmacology of methamphetamine. Addiction 104 (2009), 1085–1099.
30. [30] Ross, E.A., Reisfield, G.M., Watson, M.C., Chronister, C.W., Goldberger, B.A., Psychoactive bath salts intoxication with methylenedioxypyrovalerone. Am. J. Med. 125 (2012), 854–858.
31. [31] Zhang, X., Banerjee, A., Banks, W.A., Ercal, N., N-Acetylcysteine amide protects against methamphetamine-induced oxidative stress and neurotoxicity in immortalized human brain endothelial cells. Brain Res. 1275 (2009), 87–95.
32. [32] Seo, J.W., Jones, S.M., Hostetter, T.A., Iliff, J.J., West, G.A., Methamphetamine induces the release of endothelin. J. Neurosci. Res. 94 (2016), 170–178.
33. [33] Ramirez, S.H., Potula, R., Fan, S., Eidem, T., Papugani, A., Reichenbach, N., Dykstra, H., Weksler, B.B., Romero, I.A., Couraud, P.O., Persidsky, Y., Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells. J. Cereb. Blood Flow Metab. 29 (2009), 1933–1945.
34. [34] Martins, T., Burgoyne, T., Kenny, B.A., Hudson, N., Futter, C.E., Ambrosio, A.F., Silva, A.P., Greenwood, J., Turowski, P., Methamphetamine-induced nitric oxide promotes vesicular transport in blood-brain barrier endothelial cells. Neuropharmacology 65 (2013), 74–82.
35. [35] Argaw, A.T., Asp, L., Zhang, J., Navrazhina, K., Pham, T., Mariani, J.N., Mahase, S., Dutta, D.J., Seto, J., Kramer, E.G., Ferrara, N., Sofroniew, M.V., John, G.R., Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J. Clin. Invest. 122 (2012), 2454–2468.
36. [36] Chi, O.Z., Hunter, C., Liu, X., Weiss, H.R., Effects of VEGF and nitric oxide synthase inhibition on blood-brain barrier disruption in the ischemic and non-ischemic cerebral cortex. Neurol. Res. 27 (2005), 864–868.
37. [37] Ma, J., Wan, J., Meng, J., Banerjee, S., Ramakrishnan, S., Roy, S., Methamphetamine induces autophagy as a pro-survival response against apoptotic endothelial cell death through the Kappa opioid receptor. Cell. Death Dis., 5, 2014, e1099.
38. [38] Valente, M.J., Araujo, A.M., Silva, R., Bastos, M.L., Carvalho, F., Guedes de Pinho, P., Carvalho, M., 3,4-Methylenedioxypyrovalerone (MDPV): in vitro mechanisms of hepatotoxicity under normothermic and hyperthermic conditions. Arch. Toxicol., 2015.
39. [39] Valente, M.J., Araújo, A.M., d. Bastos, M.L., Fernandes, E., Carvalho, F., Guedes de Pinho, P., Carvalho, M., Characterization of hepatotoxicity mechanisms triggered by designer cathinone drugs (β-keto amphetamines). Toxicol. Sci., 2016, 10.1093/toxsci/kfw105.
40. [40] Simmler, L.D., Buser, T.A., Donzelli, M., Schramm, Y., Dieu, L.H., Huwyler, J., Chaboz, S., Hoener, M.C., Liechti, M.E., Pharmacological characterization of designer cathinones in vitro. Br. J. Pharmacol. 168 (2013), 458–470.
41. [41] Kiyatkin, E.A., Kim, A.H., Wakabayashi, K.T., Baumann, M.H., Shaham, Y., Effects of social interaction and warm ambient temperature on brain hyperthermia induced by the designer drugs methylone and MDPV. Neuropsychopharmacology 40 (2015), 436–445.
42. [42] Kousik, S.M., Napier, T.C., Ross, R.D., Sumner, D.R., Carvey, P.M., Dopamine receptors and the persistent neurovascular dysregulation induced by methamphetamine self-administration in rats. J. Pharmacol. Exp. Ther. 351 (2014), 432–439.
43. [43] Polesskaya, O., Silva, J., Sanfilippo, C., Desrosiers, T., Sun, A., Shen, J., Feng, C., Polesskiy, A., Deane, R., Zlokovic, B., Kasischke, K., Dewhurst, S., Methamphetamine causes sustained depression in cerebral blood flow. Brain Res. 1373 (2011), 91–100.
44. [44] Wakabayashi, K.T., Ren, S.E., Kiyatkin, E.A., Methylenedioxypyrovalerone (MDPV) mimics cocaine in its physiological and behavioral effects but induces distinct changes in NAc glucose. Front. Neurosci., 9, 2015, 324.
45. [45] Baker, K.E., Herbert, A.A., Broadley, K.J., Vasoconstriction of porcine left anterior descending coronary artery by ecstasy and cathinone is not an indirect sympathomimetic effect. Vasc. Pharmacol. 47 (2007), 10–17.
46. [46] Kiyatkin, E.A., Kim, A.H., Wakabayashi, K.T., Baumann, M.H., Shaham, Y., Critical role of peripheral vasoconstriction in fatal brain hyperthermia induced by MDMA (Ecstasy) under conditions that mimic human drug use. J. Neurosci. 34 (2014), 7754–7762.